What is new in familial hypercholesterolemia?

Current Opinion in Lipidology

Volumn 25, Issue 3, 2014, Pages 183-188

  Santos, Raul D ^a   Maranhao, Raul C ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Atherosclerosis; familial hypercholesterolemia; genes; LDL; proprotein convertase subtilisin kexin type 9

Indexed keywords

ALIROCUMAB; APOLIPOPROTEIN B; EVOLOCUMAB; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOMITAPIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MIPOMERSEN; PLACEBO; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; PROTEINASE; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; DRUG DOSE ESCALATION; FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; ISCHEMIC HEART DISEASE; LIPID METABOLISM; MOLECULAR DIAGNOSIS; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; BLOOD; GENETICS; HYPERCHOLESTEROLEMIA; LIPID METABOLISM, INBORN ERRORS; METABOLISM; MUTATION;

APOLIPOPROTEINS B; ATHEROSCLEROSIS; CHOLESTEROL, LDL; HUMANS; HYPERCHOLESTEROLEMIA; LIPID METABOLISM, INBORN ERRORS; MUTATION; RECEPTORS, LDL; RISK FACTORS;

EID: 84900562085     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0000000000000073     Document Type: Review

References (34)

1. Nordestgaard BG, Chapman MJ, Humphri es SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: Guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society. Eur Heart J 2013; 34:3478-3490.
2. Benn M, Watts GF, Tybjaerg-Hansen A, Nordestgaard BG. Familial hypercholesterolemia in the Danish general population: Prevalence, coronary artery disease, and cholesterol-lowering medication. J Clin Endocrinol Metab 2012; 97:3956-3964.
3. Versmissen J, Oosterveer DM, Yazdanpanah M, et al. Efficacy of statins in familial hypercholesterolaemia: A long term cohort study. BMJ 2008; 337: A2423.
4. Lagace TA, Curtis DE, Garuti R, et al. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J Clin Invest 2006; 116:2995-3005.
5. Raal F, Panz V, Immelman A, Pilcher G. Elevated PCSK9 levels in untreated patients with heterozygous or homozygous familial hypercholesterolemia and the response to high-dose statin therap y. J Am Heart Assoc 2013; 2:e000028.
6. Sniderman AD, Qi Y, Ma CI, et al. Hepatic cholesterol homeostasis: Is the lowdensity lipoprotein pathway a regulatory or a shunt pathway Arterioscler Thr omb Vasc Biol 2013; 33:2481-2490.
7. Sposito AC, Lemos PA, Santos RD, et al. Impaired intravascular triglyceride lipolysis constitutes a marker of clinical outcome in patients with stable angina unde rgoing secondary prevention treatment: A long-term follow-up study. J Am Coll Cardiol 2004; 43:2225-2232.
8. Carneiro MM, Miname MH, Gagliardi AC, et al. The removal from plasma of chylomicrons a nd remnants is reduced in heterozygous familial hypercholesterolemia subjects with identified LDL receptor mutations: Study with artificial emulsions. Atherosclerosis 2012; 221:268-274.
9. Guerin M. Reverse cholesterol transport in familial hypercholesterolemia. Curr Opin Lipidol 2012; 23:377-385.
10. Li C, Zhang W, Zhou F, et al. Cholesteryl ester transfer protein inhibitors in the treatment of dyslipidemia: A systematic review and meta-analysis. PLoS One 2013; 8:e77049.
11. Martinez LR, Sa ntos RD, Miname MH, et al. Transfer of lipids to high-density lipoprotein (HDL) is altered in patients with familial hypercholesterolemia. Metabolism 2013; 62:1061-1064.
12. Watts GF,Gidding S,Wierzbicki AS,et al. Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. Int J Cardiol, 2014, 171, 309-325.
13. Fahed A, Nemer GM. Famili al hypercholesterolemia: The lipids or the genes Nutr Metab (Lond) 2011; 8:23.
14. Vandrovcova J, Thomas ER, Atanur SS, et al. The use of next-generation sequencing in clinical diagnosis of familial hypercholesterolemia. Genet Med 2013; 15:948-957.
15. Taylor A, Wang D, Patel K, et al. Mutation detection rate and spectrum in familial hypercholesterolaemia patients in the UK pilot cascade p roject. Clin Genet 2010; 77:572-580.
16. Talmud PJ, Shah S, Whittall R, et al. Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: A case-control study. Lancet 2013; 381:1293-1301.
17. Teslovich TM, Musunuru K, Smith AV, et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2010; 466:707-713.
18. Hadfield SG, Horara S, Starr BJ, et al. Family tracing to identify patients with familial hypercholesterolaemia: The second audit of the Department of Health familial hypercholesterolaemia cascade testing project. Ann Clin Biochem 2009; 46:24-32.
19. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Choles terol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013. doi: 10.1016/j.jacc.2013.11.002. [Epub ahead of print]
20. Napoli C, Glass CK, Witztum JL, et al. Influence of maternal hypercholesterolaemia during pregnancy on progression of early atherosclerotic lesions in childhood: Fate of Early Lesions in Children (FELIC ) study. Lancet 1999; 354:1234-1241.
21. Berge LN, Arnesen E, Forsdahl A. Pregnancy related changes in some cardiovascular risk factors. Acta Obstet Gynecol Scand 1996; 75:439-442.
22. Kusters DM, Avis HJ, Braamskamp MJ, et al. Inheritance pattern of familial hypercholesterolemia and markers of cardiovascular risk. J Lipid Res 2013; 54:2543-2549.
23. Miname MH, Ribeiro MS 2nd, Parga Filho, et al. Evaluation of subclinical atherosclerosis by computed tomography coronary angiography and its association with risk factors in familial hypercholesterolemia. Atherosclerosis 201 0; 213:486-491.
24. Hobbs HH, Russell DW, Brown MS, Goldstein JL. The LDL receptor locus in familial hyperchole sterolemia: Mutational analysis of a membrane protein. Annu Rev Genet 1990; 24:133-170.
25. Ten Kate GJ, Neefjes LA, Dedic A, et al. The effect of LDLR-negative genotype on CT coronary atheroscle rosis in asymptomatic statin treated patients with heterozygous familial hypercholesterolemia. Atherosclerosis 2013; 227: 334-341.
26. Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipop rotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: A randomised, double-blind, placebo-controlled trial. Lancet 2010; 375:998-1006.
27. Stein EA, Dufour R, Gagne C, et al. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: Results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safe ty as add-on therapy in patients with coronary artery disease. Circulation 2012; 126:2283-2292.
28. Santos RD, Duell PB, East C, et al. Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim eht549. [Epub ahead of print]
29. Cuchel M, Meagher EA, du Toit Theron H, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in pati ents with homozygous familial hypercholesterolaemia: A single-arm, open-label, phase 3 study. Lancet 2013; 381:40-46.
30. Stein EA, Gipe D, Bergeron J, et al. Effect of a monoclonal antibody to PCSK9 , REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: A phase 2 randomised controlled trial. Lancet 2012; 380 :29-36.
31. Raal F, Scott R, Somaratne R, et al. Low-density lipoprotein cholesterollowering effects ofAMG145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: The Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation 2012; 126:2408-2417.
32. . Stein EA. Low-density lipoprotein cholesterol reduction by inhibition of PCSK9. Curr Opin Lipidol 2013; 24:510-517.
33. Koren MJ,Giugliano RP,Raal FJ,et al. Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial. Circulation, 2014, 129, 234-243.
34. Stein EA, Honarpour N, Wasserman SM, et al. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation 2013; 128:21 13-2120.